More PI Diagnoses Covered for Home Ig Replacement Therapy under Medicare Part B
Over the past year, the Immune Deficiency Foundation (IDF) has worked with the Centers for Medicare and Medicaid Services (CMS) to expand access to immunoglobulin (Ig) replacement therapy for Medicare beneficiaries. In particular, IDF has advocated to expand Medicare Part B coverage for in-home Ig replacement therapy to include more PI diagnoses.
Read MoreThe Immunoglobulin Shortage: A Plea to Hospital-Based Prescribers and Pharmacists
By John G. Boyle, President & CEO As the national patient organization for people living with primary immunodeficiency diseases (PI), the Immune Deficiency Foundation (IDF) continues to hear troubling reports about challenges patients are facing in accessing immunoglobulin (Ig) products. We are hearing these stories in alarming frequency both
Read MoreImmunoglobulin Availability: New Battlefronts, Continuing Advocacy
By: John G. Boyle, President & CEO Each day, members of the Immune Deficiency Foundation (IDF) team hear new stories from families affected by primary immunodeficiency diseases (PI) about their challenges in accessing immunoglobulin (Ig) products. Many are a variation on the theme that we’ve been hearing all year. Some, however, show that the
Read MoreUrgent: Biologic Withdrawal Information for Gamunex
Grifols Therapeutics LLC has initiated a voluntary withdrawal of Gamunex. Click here to read the notification from the Patient Notification System.
Read MoreThank You for Joining Us at the IDF 2019 National Conference
The IDF 2019 National Conference, held in National Harbor, MD, June 20-22, brought together more than 1,300 attendees from 42 states, Washington, DC, and Australia, Canada, England, Germany, Iceland, Israel, Norway, and Portugal. This was the first IDF National Conference for 590 attendees. More than 80 educational sessions filled each day
Read More
